E Fund Management Co. Ltd. lowered its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 10.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,395 shares of the company’s stock after selling 865 shares during the period. E Fund Management Co. Ltd.’s holdings in Vera Therapeutics were worth $268,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its holdings in Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares during the period. Cetera Advisors LLC acquired a new stake in shares of Vera Therapeutics in the first quarter valued at approximately $235,000. Capstone Investment Advisors LLC bought a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $248,000. Pale Fire Capital SE acquired a new position in shares of Vera Therapeutics during the 4th quarter worth approximately $252,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Vera Therapeutics by 30.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after acquiring an additional 1,737 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.
Insider Activity
In related news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total value of $585,937.50. Following the transaction, the chief executive officer now owns 307,972 shares in the company, valued at $11,548,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 21.70% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Vera Therapeutics
Vera Therapeutics Price Performance
NASDAQ:VERA opened at $41.99 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -20.48 and a beta of 0.99. Vera Therapeutics, Inc. has a 52 week low of $9.24 and a 52 week high of $50.78. The firm’s 50-day simple moving average is $37.26 and its 200 day simple moving average is $39.09.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). As a group, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Recommended Stories
- Five stocks we like better than Vera Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What is the Australian Securities Exchange (ASX)
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.